ABSTRACT
Many high-income countries have met the SARS-CoV-2 pandemic with overwhelming sequencing resources and have identified numerous distinct lineages, including some with notably altered biology. Over a year into the pandemic following unprecedented reductions in worldwide human mobility, distinct introduced lineages of SARS-CoV-2 without sequenced antecedents are increasingly discovered in high-income countries as a result of ongoing SARS-CoV-2 genomic surveillance initiatives. We here describe one such SARS-CoV-2 lineage, carrying many mutations and deletions in the spike protein shared with widespread variants of concern (VOCs), including E484K, S477N and deletions HV69Δ, Y144Δ, and LLA241/243Δ. This lineage – designated B.1.620 – is known to circulate in Lithuania and has now been found in several European states, but also in increasing numbers in central Africa owing to important recent increases in genome sequencing efforts on the continent. We provide evidence of likely ongoing local transmission of B.1.620 in Lithuania, France, Germany, Spain, Belgium and the Central African Republic. We describe the suite of mutations this lineage carries, its potential to be resistant to neutralising antibodies, travel histories for a subset of the European cases, and evidence of local B.1.620 transmission in Europe. We make a case for the likely Central African origin of this lineage by providing travel records as well as the outcomes of carefully crafted phylogenetic and phylogeographic inference methodologies, the latter of which is able to exploit individual travel histories recorded for infected travellers having entered different European countries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SLH acknowledges support from the Research Foundation - Flanders ("Fonds voor Wetenschappelijk 501 Onderzoek - Vlaanderen," G0D5117N). BP and GB acknowledges support from the Internal Fondsen KU 502 Leuven/Internal Funds KU Leuven (Grant No. C14/18/094). GB acknowledges support from the Research 503 Foundation - Flanders ("Fonds voor Wetenschappelijk Onderzoek - Vlaanderen," G0E1420N, G098321N). 504 FHL and TFN were supported by WWF and German Research Council's grant LE1813/14-1 (Great Ape 505 Health in Tropical Africa), Research in CAR took place under permit #098/MRSIT/DIRCAB/CB.20, 506 granted to TT by the Ministery of Scientific Research and Technological Innovation. JS acknowledges 507 funding from the Dutch Research Council NWO Gravitation 2013 BOO, Institute for Chemical Immunol- 508 ogy (ICI; 024.002.009). AMJJB acknowledges the support of European Union Horizon 2020 projects 509 BioExcel (823830) and EOSC-Hub (777536) projects. AA and CB acknowledge the support of the French 510 National Research Institute for Sustainable Development (IRD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Lithuanian Bioethics Committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data allowed to be distributed and scripts to reproduce analyses and figures are available at https://github.com/evogytis/B.1.620-in-Europe
